Focusing on cancer treatment HistoSonic, $102 million received investment. The company’s $102 million D series investment round, Alpha Wave Ventures Managed by. In the investment round of US-based HistoSonic Amzak Health, HealthQuest Capital, Johnson & Johnson Innovation, Venture Investors, Lumira Ventures, Yonjin Venture ve the State of Wisconsin’s investment took place.
HistoSonics said it will use the new investment to accelerate the commercial development of its histotripsy technology, fund clinical studies for liver and other types of cancer, and expand the company’s operations.
in 2009 Brian Fowlkes, M. Christine Gibbons ve Thomas Davison The established company is defined as a biotechnology company focusing on cancer treatment. The company has developed a treatment method called histotripsy, which destroys cancerous tissues with sound waves, and based on this technology Edison He produced a system called .
The Edison system works with focused ultrasound waves and creates high-pressure microbubbles within the targeted tumor. The bubbles rapidly expand and burst, mechanically breaking down and liquefying the cancer cells without damaging the healthy tissues surrounding the tumor. This process; It minimizes side effects compared to traditional methods such as surgery, radiation or chemotherapy.
Histotripsy technology focuses on destroying tumors without the need for needles or incisions. This treatment method was originally developed for liver cancer. The effectiveness of the technology is currently being investigated in various tumor types such as kidney, pancreas, prostate and brain.
Source link: https://webrazzi.com/2024/08/16/kanser-tedavisine-odaklanan-histosonic-102-milyon-dolar-yatirim-aldi/